Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Company Deals

HBM Holdings and Lannacheng Biotech Forge Strategic Alliance for Next‑Generation RDCs in Precision Oncology

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Fineline Cube Dec 30, 2025
Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Fineline Cube Dec 30, 2025
Company Deals Hospital

Prudential Hong Kong Collaborates with Foshan Fosun Chancheng Hospital for Direct Payment Services

Fineline Cube May 9, 2025

Prudential Hong Kong Limited, a subsidiary of UK-based Prudential plc, has entered into a strategic...

Company Deals

Sanyou Medical Partners with CGBio to Launch Regenerative Medicine Joint Venture

Fineline Cube May 9, 2025

China-based Shanghai Sanyou Medical Co., Ltd (SHA: 688085) announced plans to establish a joint venture...

Company Drug

Hengrui Pharma Files for New Dalpiciclib Indication in Early Breast Cancer

Fineline Cube May 9, 2025

China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that a new indication approval filing...

Company Deals

Gilead Sciences Announces $11 Billion Investment in US Expansion

Fineline Cube May 9, 2025

US-based major Gilead Sciences Inc. (NASDAQ: GILD) announced an additional investment of USD 11 billion...

Company Drug

Humanwell Healthcare Gains NMPA Approval for Giapreza Generic in Shock Therapy

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clinical trial...

Company Drug

Humanwell Healthcare Gains NMPA Clearance for HZ-J001 Cream in Vitiligo Trial

Fineline Cube May 9, 2025

China-based Humanwell Healthcare (Group) Co., Ltd (SHA: 600079) announced that it has received clearance from...

Company Deals

Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area

Fineline Cube May 9, 2025

US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...

Company Deals

Insilico Medicine Files for IPO to Leverage AI in Drug Discovery

Fineline Cube May 9, 2025

China-based Insilico Medicine, a biotech company leveraging generative artificial intelligence (AI), has filed for an...

Company Drug

Pfizer’s Zavicefta Approved by China’s NMPA for Severe Infections in All Ages

Fineline Cube May 9, 2025

US-based pharmaceutical giant Pfizer (NYSE: PFE) announced that it has received market approval from China’s...

Company Drug

Amgen’s Tepezza Approved in UK for Thyroid Eye Disease Treatment

Fineline Cube May 9, 2025

US biotech Amgen (NASDAQ: AMGN) announced that the UK’s Medicines and Healthcare products Regulatory Agency...

Company Deals

Guangzhou Regenverse Therapeutics Raises RMB 100 Million in Pre-Series A Financing

Fineline Cube May 8, 2025

China-based Guangzhou Regenverse Therapeutics Co., Ltd (former name: Guangzhou Regen Therapeutics Co., Ltd.), a developer...

Company

Novo Nordisk Reports 18% YOY Revenue Growth in Q1 2025

Fineline Cube May 8, 2025

Denmark-based Novo Nordisk (NYSE: NVO, CPH: NOVO-B) released its Q1 2025 earnings report this week....

Company Deals Drug

Sino Biopharmaceutical and JD Healthcare Forge Comprehensive Strategic Partnership

Fineline Cube May 8, 2025

China-based Sino Biopharmaceutical Ltd (HKG: 1177) and JD Healthcare, a unit of China’s e-commerce giant...

Company Deals

Adicon Holdings Acquires Suzhou Youqin Medical Laboratory and Yuande Weikang

Fineline Cube May 8, 2025

China-based independent clinic laboratory (ICL) service provider Adicon Holdings Ltd (HKG: 9860) announced the acquisition...

Company Deals

Oricell Partners with Umoja Biopharma to Develop In Vivo CAR-T Cell Therapies

Fineline Cube May 8, 2025

China-based Oricell Therapeutics Co., Ltd. announced a strategic partnership agreement with US-headquartered Umoja Biopharma Inc....

Company

BeiGene’s Q1 2025 Revenues Soar 49% YOY, Driven by Brukinsa Global Sales

Fineline Cube May 8, 2025

BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235), a China-based oncology specialist proposing to change...

Company Drug

European Commission Approves J&J’s Tremfya for Crohn’s Disease Treatment

Fineline Cube May 8, 2025

Johnson & Johnson (J&J, NYSE: JNJ) announced that the European Commission (EC) has approved Tremfya...

Company

Amgen Reports 9% Revenue Growth in Q1 2025, Driven by Double-Digit Product Sales

Fineline Cube May 8, 2025

US biotech Amgen (NASDAQ: AMGN) revealed its 2025 Q1 financial results, recording USD 8.1 billion...

Company Drug

AstraZeneca and Daiichi Sankyo Announce Positive DESTINY-Breast11 Trial Results for Enhertu

Fineline Cube May 8, 2025

Partners AstraZeneca (NASDAQ: AZN) and Daiichi Sankyo (TYO: 4568) announced the positive preliminary results from...

Company

Siemens Healthineers Reports Q2 2025 Revenue Up 6.8% to EUR 5.909 Billion

Fineline Cube May 8, 2025

Germany-based Siemens Healthineers AG (ETR: SHL) released its financial report for the second quarter of...

Posts pagination

1 … 102 103 104 … 602

Recent updates

  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
  • TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China
  • Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Company Drug

Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial

Company Drug

TJ Biopharma and Jumpcan Secure BE Trial Approval for Localized Eftansomatropin in China

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.